The prognostic role of CD68 and FoxP3 expression in patients with primary central nervous system lymphoma

Annals of Hematology
Hyunsoo ChoJin Seok Kim

Abstract

The prognostic role of CD68 and FoxP3 in primary central nervous system lymphoma (PCNSL) has not been evaluated. Thus, we examined the prognostic significance of CD68 and FoxP3 expression in tumor samples of 76 newly diagnosed immunocompetent PCNSL patients. All patients were treated initially with high-dose methotrexate (HD-MTX)-based chemotherapy, and 16 (21.1%) patients received upfront autologous stem cell transplantation (ASCT) consolidation. High expression of CD68 (>55 cells/high-power field) or FoxP3 (>15 cells/high-power field) was observed in 10 patients, respectively. High CD68 expression was associated with inferior overall survival (OS) and progression-free survival (PFS) in multivariate analysis (P = 0.023 and P = 0.021, respectively). In addition, we performed subgroup analysis based on upfront ASCT. High CD68 expression was also associated with inferior OS and PFS in multivariate analysis (P = 0.013 and P < 0.001, respectively) among patients who did not receive upfront ASCT (n = 60), but not in patients who received upfront ASCT. The expression of FoxP3 was not significantly associated with survival. Therefore, we identified a prognostic significance of high CD68 expression in PCNSL, which suggests a need for f...Continue Reading

References

Jan 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrés J M FerreriFranco Cavalli
Jun 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lauren E AbreyUNKNOWN International Primary CNS Lymphoma Collaborative Group
Nov 23, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lauren E AbreyLisa M DeAngelis
Jun 9, 2007·British Journal of Haematology·M PonzoniUNKNOWN International Extranodal Lymphoma Study Group
Jan 11, 2008·Blood·Han W TunMichael McKinney
May 2, 2008·Cancer Letters·Antonio SicaAlberto Mantovani
Mar 12, 2010·The New England Journal of Medicine·Christian SteidlRandy D Gascoyne
Sep 28, 2010·International Journal of Cancer. Journal International Du Cancer·Daniel VenetzMariagrazia Uguccioni
Nov 23, 2011·Journal of Clinical and Experimental Hematopathology : JCEH·Yoshihiro KomoharaMotohiro Takeya
Mar 19, 2013·Neuro-oncology·Gareth GregoryStephen Opat
May 15, 2013·Nature Reviews. Neurology·Agnieszka Korfel, Uwe Schlegel
Dec 24, 2013·Clinical Neuropathology·Anna Sophie BerghoffMatthias Preusser
Jan 27, 2015·Neuro-oncology·Alissa A ThomasCamilo E Fadul
Aug 29, 2016·Journal of Experimental & Clinical Cancer Research : CR·Iole CordoneCarmine M Carapella

❮ Previous
Next ❯

Citations

Sep 19, 2017·Current Opinion in Neurology·Louis Royer-PerronAgusti Alentorn
May 19, 2020·Journal of Cellular Physiology·Hua YangHua You
Mar 27, 2018·Neuropathology : Official Journal of the Japanese Society of Neuropathology·Masaki KohSatoshi Kuroda
Jun 21, 2020·Cancers·Thomas RoetzerAdelheid Woehrer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.